© Drug Hunter Inc. 2018-2023
Home > “compound 60b”
RSV D486N-mut. fusion protein inh.
oral antiviral clinical candidate
from lower barrier to atropisomerism of lead
Bioorg. Med. Chem., Oct. 31, 2020
Taisho Pharmaceutical, Saitama, JP
“compound 60b” (Taisho D486N mutant RSV fusion protein inhibitor clinical candidate)
Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.
Request a trial to access insights powering the pros in our industry.
Molecules of the Month
Molecule of the Year